All analyses

Insulet Corporation (PODD) Stock Analysis

Score A+

Growth · Grade A · Bearish

Healthcare · Medical Devices

$153.56

Fair Value

$311.31

+102.7%

Conviction

10/10

Quality

A

Classification

Growth

Investment Thesis

High quantitative score: Solid company with strong risk/reward at 10.0:1.

For New Investors

Quantitative score: high

For Current Holders

Quantitative score: neutral

Buy if

  • Price drops 15-20% (improves asymmetry)
  • Bull scenario catalysts materialize
  • Market-wide correction creates opportunity

Sell if

  • Bear scenario triggers occur
  • Quality metrics deteriorate (ROIC declining)
  • Better alternatives emerge

Valuation

Fair Value estimate: $311.31 (+102.7%). Significantly undervalued.

PEG-Based EPS

$449.56

FCF DCF Model

$334.38

EV/EBITDA

$248.64

Blended Fair Value

$311.31

Confidence

Medium

Methods

PEG-Based EPS, FCF 2-Stage DCF, EV/EBITDA, Revenue Multiple

Quality Analysis

A

114/120 points

Investable

ROE (3Y Avg)

26.3%

ROIC-WACC Spread

7.6%

D/E Ratio

0.7x

Current Ratio

2.8x

Interest Coverage

6x

FCF Positive Years

3/3

Quality Flags

  • ROIC spread: 7.6pp (got 19/25 pts)
  • Leverage: D/E 0.7x (10/15 pts)

Market Sentiment

Wall Street Consensus

$237.00

+54.3% Upside

24 analysts

Range: $198.00$280.00

Rating: Buy

Our model is slightly more bullish than Wall Street.

Trend & Technical

Bearish

Price ($153.55) is 44.0% below SMA 200 ($274.12). Bearish trend. Caution on entry.

Technical Score41/100

Tech Score 41/100 — Weak technicals. Bearish bias in trend or momentum.

Risk & Reward

Asymmetry Ratio

10.00:1

Expected Return

+95.9%

Bull Upside

+172.1%

Bear Downside

-10.0%

Excellent asymmetry: >3:1 ratio. Upside significantly outweighs downside.

Verdict: Very Favorable

Scenario Analysis

Bear

Base

Bull

Buy Zone & Action Plan

See exact entry zones, stop-loss levels, and a personalized action plan.

Access free

AI Executive Summary

Get a detailed AI-written breakdown of the investment thesis, risks, and catalysts.

Access free

Technical Analysis

RSI, MACD, moving averages, trend signals, and momentum indicators.

Access free

Ask AI about this stock

Chat with our AI analyst to ask questions about valuation, risks, or comparisons.

Access free

Frequently Asked Questions

What is the fair value of PODD?

Based on our multi-method conviction analysis, the estimated fair value of Insulet Corporation (PODD) is $311.31. This is calculated by blending PEG-Based EPS, FCF 2-Stage DCF, EV/EBITDA, Revenue Multiple and applying a quality premium of 0% based on the company's fundamentals. The confidence level of this estimate is medium.

Is PODD a buy, sell, or hold?

PODD currently has a STRONG_BUY rating with a conviction score of 10/10. High quantitative score: Solid company with strong risk/reward at 10.0:1. Quantitative score: high.

Is PODD a high-quality stock?

Insulet Corporation has a quality grade of A (114/120 points), rated as Investable. Key metrics include ROE of 26.3%, ROIC-WACC spread of 7.6%, and D/E ratio of 0.7x.

What type of stock is PODD?

PODD is classified as a "growth" in our framework. High revenue growth: 26.9%, High P/E: 35.9x, Low dividend (reinvesting): 0.0%, Strong ROE: 21.4%, Market-like beta: 1.20

What do Wall Street analysts say about PODD?

24 Wall Street analysts have a consensus price target of $237.00 for PODD, representing +54.3% upside. Targets range from $198.00 to $280.00. The consensus recommendation is "Buy". Our model is slightly more bullish than Wall Street.

What are the risks of investing in PODD?

The risk/reward asymmetry ratio for PODD is 10.00:1, rated as Very Favorable. Excellent asymmetry: >3:1 ratio. Upside significantly outweighs downside. The expected return is +95.9%, with bull case upside of +172.1% and bear case downside of -10.0%.

What is the current trend for PODD?

PODD is in a bearish trend. Price ($153.55) is 44.0% below SMA 200 ($274.12). Bearish trend. Caution on entry. The technical score is 41/100.

Related Stock Analyses

Best Stocks to Buy

Get the complete analysis

Scenario targets, buy zones, action plan, executive summary, technical analysis, and AI chat. All free.

Last updated: May 19, 2026 · Framework version 3.7

This analysis is for informational purposes only and should not be considered financial advice. Always do your own research before making investment decisions.